News & Events
Thursday, November 07, 2024
• Strong engagement: more than 90% of owners participated in the Annual Shareholder Meeting where capital raise was announced, showing solid commitment to Vidac’s mission. • Vidac initiates preparation for Phase second 2b study in skin cancer: will...
Sunday, November 03, 2024
London (UK), October 30 2024 (11:00 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, held its Annual...
Tuesday, October 08, 2024
THIS PUBLICATION IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this publication or as to the action you should take, you should seek your own advice from an authorised...
Tuesday, October 08, 2024
Proxy appointment For the purposes of voting on the Annual General Meeting of shareholders of VIDAC PHARMA HOLDING PLC (Name of the shareholder) (Address of the shareholder) Date:__ October 2024 Sent via email VIDAC PHARMA HOLDING PLC (Company...
Thursday, September 19, 2024
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces that the...
Thursday, July 25, 2024
London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces...
Monday, June 03, 2024
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it...
Monday, April 29, 2024
London (UK), April 29, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced it...
Wednesday, March 27, 2024
London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it...
Monday, March 11, 2024
London (UK), March 11, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced it has...
Monday, February 19, 2024
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today...
Monday, February 12, 2024
London (UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces...
Tuesday, February 06, 2024
London ( UK), February 6, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces it...
Monday, January 29, 2024
London ( UK), January 29, 2024 – – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces...
Monday, January 22, 2024
London (UK), January 22, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, at an international...
Monday, January 15, 2024
London (UK), January 15, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, will present its...
2023 Press Releases
Tuesday, December 19, 2023
London (UK), Rehovot (Israel), December 19th 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed preparations for a Phase 2b trial of...
Wednesday, November 29, 2023
London (UK), Rehovot (Israel), 29 November 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, today announced results from an in vitro study of...
Monday, November 13, 2023
Vidac Pharma is happy to inform that it received an official Notice of Allowance from the US Patent Office (USPTO) for its new Patent on a new Chemical synthesis pathway for production of its Drug Candidate VDA1102 presently in Clinical Stage....
Thursday, October 26, 2023
London (UK), Rehovot (IL), October 26th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding Plc is happy to announce Granting of a new Patent in China One of the most important...
Monday, October 23, 2023
London (UK), Rehovot (IL), October 23rd, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding Plc is proud to announce that Vidac Pharma Ltd, its operational arm received high...
Tuesday, October 17, 2023
London (UK), Rehovot (IL), October 17th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Ltd, the operational company, which is a wholly owned subsidiary of Vidac Pharma Holding Plc,...
Sunday, October 01, 2023
London (UK), Rehovot (IL), October 2nd, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com More than 80% of the Shareholders were present or represented by Proxy. The Shareholders voted unanimously for...
Wednesday, September 13, 2023
London (UK), Rehovot (IL), 13 th September 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding Plc will hold its Annual Shareholders Meeting in person and on-line on Sept 29th at...
Wednesday, August 30, 2023
London (UK), Rehovot (IL), Paris (FR) August 30h, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Under the Organization of Dr Alain Herrera previously head of the Oncology Franchise at Sanofi around...
Sunday, August 20, 2023
London (UK), Rehovot (Israel) Tel Hashomer (Israel) August, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma announces a Research Collaboration and License Agreement with Sheba Medical...
Tuesday, August 15, 2023
London (UK), Rehovot (Israel) Wuppertal (Germany) August 15th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma is proud to announce that its next pre-Phase 3 Clinical trial on advanced...
Friday, August 11, 2023
London (UK), Rehovot (Israel) August 11th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com London August 11. Vidac Pharma Holding Plc announced that from today August 11, its shares will be dual...
Thursday, August 10, 2023
London (UK), Rehovot (Israel) August 10 th , 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com London UK. The extraordinary meeting of Shareholders which took place on August 8 th in person and...
Wednesday, July 26, 2023
London (UK), Rehovot (Israel) July 26th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma to hold Extraordinary Shareholder Meeting to prepare for potential investments. Vidac Pharma...
Monday, July 17, 2023
London (UK), Rehovot (Israel) Lille (France) July 17th , 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Poor predictability of animal models is one of the most time and money consuming step in...
Monday, July 10, 2023
Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference London (UK) and Rehovot (Israel) July 10th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ)....
Wednesday, July 05, 2023
London (UK) and Rehovot (Israel) July 5th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma was invited to organize a Round Table discussion on its new paradigm for Drug Discovery: the...
Tuesday, June 27, 2023
London (UK) and Rehovot (Israel) June 27th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com The preliminary results on more than 50% of the planned number of patients in this rare disease shows a...
Thursday, June 15, 2023
London (UK) and Rehovot (Israel) June 16th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). ( www.vidacpharma.com ) As one of three laureate of the Prize for Innovation it received during the Paris HealthTech Innovation...
Tuesday, April 25, 2023
London (UK) and Rehovot (Israel) April 26, 2023 Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). ( www.vidacpharma.com ) In preparation for its new status as a public company registered in the Hamburg stock Exchange (T9G, WKN:...
Sunday, April 23, 2023
London (UK) and Rehovot (Israel) April 24, 2023 Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). ( www.vidacpharma.com ) Vidac Pharma Holding Plc. Informs of automatic expiration of a share purchase facility agreement with...
Thursday, March 30, 2023
London (UK) and Rehovot (Israel). VIDAC PHARMA HOLDING PLC (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). ( www.vidacpharma.com ) is happy to announce a listing of company shares in the Hamburg Stock Exchange. Vidac Pharma is a clinical stage company...
Earlier Press Releases
Thursday, September 23, 2021
Rehovot, Israel Sept 20, 2021 Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions. “We are very satisfied with the...
Monday, September 13, 2021
Rehovot, Israel Sept 13, 2021 Vidac Pharma Ltd . announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit...
Monday, April 19, 2021
NESS -ZIONA, Israel , April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg -based private...
Tuesday, February 09, 2021
Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the...
Friday, December 14, 2018
Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol...
Saturday, November 03, 2018
Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC....
Monday, July 09, 2018
Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an...
Wednesday, June 20, 2018
Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic...
Tuesday, April 10, 2018
Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The...
Tuesday, January 23, 2018
Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO &...
Wednesday, December 06, 2017
Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum....
Thursday, October 12, 2017
Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENT in Actinic Keratosis Establishes that VDA-1102 ointment is well-tolerated, non-irritating and safe Demonstrates reduction of number of actinic keratosis...
Sunday, January 01, 2017
Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced the appointment of Dr. Chaim Brickman as the company's Chief Medical Officer, and the appointment of Dr. Vered Behar as the...
Monday, December 12, 2016
Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, in actinic keratosis (AK)...
Monday, March 13, 2017
Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has initiated a Phase 2 trial with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, to treat...
Wednesday, March 15, 2017
Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has completed a Phase 1a trial of VDA-1102 ointment, a topical ointment formulation of VDA-1102, a potent...
Wednesday, June 29, 2016
Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer and oncodermatology disease, announced today that it has closed a $9...
Thursday, February 25, 2016
Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development company, today announced the initiation of Phase I first-in-human studies with VDA-1102 ointment, its highly selective, proprietary VDAC/HK2 modulator for the...
Wednesday, December 30, 2015
Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development company, today announced the filing of an Investigational New Drug (IND) application with the U.S. FDA for VDA-1102 topical skin ointment, its highly selective,...
Wednesday, October 15, 2014
Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its vice president of clinical affairs. Chaim will oversee all clinical development...
Tuesday, August 19, 2014
Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice president of chemistry, manufacturing, and control (CMC). Dr. Salama brings to Vidac more...